{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-350349","form_type":"8-K","ticker":"NMRA","cik":"0001885522","company_name":"Neumora Therapeutics, Inc.","filed_at":"2026-08-14T11:13:22+00:00","discovered_at":"2026-08-14T11:15:01.499016+00:00","generated_at":"2026-08-14T11:15:13.202657+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Neumora appoints Joshua Pinto as CEO, narrows Q2 net loss to $43.1M","bullets":["Joshua Pinto named CEO and Board member; Paul Berns becomes Executive Chair, effective Aug 14, 2026.","Doron Sagman, M.D., appointed Chief Medical Officer; brings 20+ years of clinical development experience.","Q2 2026 net loss $43.1M vs $52.7M in Q2 2025; R&D $29.3M, G&A $12.9M; cash $116.8M as of June 30, 2026.","Pipeline: NMRA-215 IND Q4 2026, Phase 1 by end 2026; NMRA-511 MAD data Q4 2026 and Phase 2 initiation by end 2026; NMRA-898 Phase 1 data H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-350349","json":"https://secwatch.observer/filing/0001193125-26-350349.json","markdown":"https://secwatch.observer/filing/0001193125-26-350349.md","text":"https://secwatch.observer/filing/0001193125-26-350349.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1885522/000119312526350349/0001193125-26-350349-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1885522/000119312526350349/nmra-20260814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T11:15:13.202657+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1997388d8e","claim":"Joshua Pinto was appointed as Class III director at Neumora Therapeutics, Inc..","evidence_excerpt":"In connection with the Leadership Transition, on August 12, 2026, the Board also approved the appointment of Dr. Pinto as a Class III director, effective as of the Transition Date, to serve for a term expiring at the 2029 Annual Meeting of Stockholders and until his successor is elected and qualified or until his earlier death, resignation or removal.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312526350349/0001193125-26-350349-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}